A Phase 1 interventional study of Test drug: Fixed-dose combination (FDC) of gemigliptin/dapagliflozin/metformin 50/10/1000 mg and Reference drug: gemigliptin (Zemiglo) 50mg, Xigduo XR 10/1000 mg in Fed Conditions and Healthy Volunteer, sponsored by LG Chem. Completed at 1 site in South Korea. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-12.
Sponsored by LG Chem · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Bioequivalence study for the fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg under fed conditions in healthy volunteers
LG Chem is the lead sponsor of 71 studies on the registry; 8 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 1 (8%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sequence A: Test drug -\> Reference drug
Drug: Test drug: Fixed-dose combination (FDC) of gemigliptin/dapagliflozin/metformin 50/10/1000 mg · Drug: Reference drug: gemigliptin (Zemiglo) 50mg, Xigduo XR 10/1000 mg
Sequence B: Reference drug -\> Test drug
Drug: Test drug: Fixed-dose combination (FDC) of gemigliptin/dapagliflozin/metformin 50/10/1000 mg · Drug: Reference drug: gemigliptin (Zemiglo) 50mg, Xigduo XR 10/1000 mg
All participants take 1 tablet of either test drug or reference drug after meal.
Drug page: Gemigliptin
All participants take 1 tablet of either test drug or reference drug after meal.
The plasma concentration of gemigliptin, dapagliflozin, and metformin
Primary Parameters: Area under the plasma concentration versus time curve (AUClast) of gemigliptin, dapagliflozin, and metformin
Time frame: - Period 1: 16 times up to 72 hours from IP administration - Period 2: 16 times up to 72 hours from IP administration
The plasma concentration of gemigliptin, dapagliflozin, and metformin
Primary Paramenters: Peak Plasma Concentration (Cmax) of gemigliptin, dapagliflozin, and metformin
Time frame: - Period 1: 16 times up to 72 hours from IP administration - Period 2: 16 times up to 72 hours from IP administration
The plasma concentration of gemigliptin, dapagliflozin and metformin
Secondary Parameters: Time to Maximum(Tmax) Concentration of gemigliptin, dapagliflozin, and metformin
Time frame: Period 1: 16 times up to 72 hours from IP administration Period 2: 16 times up to 72 hours from IP administration
The plasma concentration of gemigliptin, dapagliflozin and metformin
Secondary Parameters: Lag Time(Tlag) of gemigliptin, dapagliflozin, and metformin
Time frame: - Period 1: 16 times up to 72 hours from IP administration - Period 2: 16 times up to 72 hours from IP administration
The plasma concentration of gemigliptin, dapagliflozin and metformin
Secondary Parameters: Area Under the Curve to Infinity(AUCinf) of gemigliptin, dapagliflozin, and metformin
Time frame: - Period 1: 16 times up to 72 hours from IP administration - Period 2: 16 times up to 72 hours from IP administration
The plasma concentration of gemigliptin, dapagliflozin and metformin
Secondary Parameters: Half-life(t1/2) of gemigliptin, dapagliflozin, and metformin
Time frame: - Period 1: 16 times up to 72 hours from IP administration - Period 2: 16 times up to 72 hours from IP administration
The plasma concentration of gemigliptin, dapagliflozin and metformin
Secondary Parameters: Apparent Clearance(CL/F) of gemigliptin, dapagliflozin, and metformin
Time frame: - Period 1: 16 times up to 72 hours from IP administration - Period 2: 16 times up to 72 hours from IP administration
The plasma concentration of gemigliptin, dapagliflozin and metformin
Secondary Parameters: Apparent Volume of Distribution(Vz/F) of gemigliptin, dapagliflozin, and metformin
Time frame: - Period 1: 16 times up to 72 hours from IP administration - Period 2: 16 times up to 72 hours from IP administration
Assessment - Safety (Adverse events)
A list of all adverse events for each treatment group and for all participants with seriousness, severity, relationship with investigational product. A number of participant with adverse event.
Time frame: up to day 18 (post study visit)
Assessment - Safety (Physical examination)
Any finding in general condition, nutritional status and other category by medical interview
Time frame: 3 times until 72 hours from IP administration
Assessment - Safety (Vital sign)
Systolic Blood Pressure(mmHg), Diastolic Blood Pressure(mmHg), Pulse Rate(beats/min), Temperature(℃)
Time frame: 7 times until 72 hours from IP administration
Assessment - Safety (12-lead ECG results)
Ventricular rate(beats/min), PR interval(msec), QRS(msec), QT(msec), QTcB(msec)
Time frame: 4 times until post-study visit
Assessment - Safety (Clinical laboratory test results)
Hematology, Blood Chemistry, Urinalysis
Time frame: 4 times until post-study visit
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2025 to primary completion in Nov 2025, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.